UnitedHealth Pursuing Payer/Pharma Collaboration To Evaluate Novel Cancer Treatments
Executive Summary
Four drug manufacturers, three payers and one genetics company are close to launching a pilot that provides pharma companies “an environment where they can supply those early testable drugs to patients anywhere with the right set of complex system biology,” UnitedHealthcare Senior VP Lee Newcomer said.
You may also be interested in...
Lung Cancer “Master Protocol” Eyed As Paradigm-Changing Approach To Drug Development
The biomarker-driven, multi-arm, multi-drug registration trial is expected to get under way in March 2014 with five drugs from different sponsors. With the promise of greater speed and efficiency in patient enrollment and late-stage development, it is being viewed as a potential model for other cancer settings.
The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development
FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.
Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say
Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.